Emily Campbell: Educating, Advocating, and Innovating for a Future Without Ovarian Cancer Delays
Healthcare awareness campaigns frequently highlight broad statistics, yet they rarely address the systemic bottlenecks that delay clinical diagnoses. When Emily Campbell evaluated the landscape of ovarian cancer advocacy, she noticed a severe disconnect between public awareness and clinical action. Through Not These Ovaries, an early-stage organization focused on patient support and education, she is targeting the specific gaps that leave women waiting years for an accurate diagnosis. Resolving those issues requires rethinking how symptoms are recognized by patients and evaluated by primary care physicians.
The Three-Year Diagnostic Gap
Diagnostic delays in ovarian cancer remain a stubborn clinical hurdle. In cases involving low-grade serous ovarian cancer, the timeline from the onset of symptoms to an accurate diagnosis averages three full years. During that extended period, subtle symptoms are routinely attributed to common digestive complaints or benign reproductive issues. When care teams miss these early signals, patients eventually enter treatment with advanced disease that is significantly harder to manage.
For Campbell, this specific diagnostic window represents the most critical barrier to patient outcomes. “When I hear the phrase ‘ovarian cancer delays,’ I think of diagnostic delay versus any other type of delay,” she notes. “The majority of the delays come from a lack of awareness, not just among women, but across the general physician and clinical group. Symptoms are often dismissed or misdiagnosed as other benign conditions, and that delay leads to more advanced disease.” Part of the diagnostic breakdown stems from clinical assumptions regarding patient demographics. This is because ovarian cancer is often perceived as an illness affecting older populations, so younger women presenting with persistent pelvic pain or bloating frequently face skepticism. Campbell points out that these demographic biases slow down clinical investigations when speed is essential. Tackling the issue requires educating family doctors and clinicians to evaluate symptoms objectively, regardless of a patient’s age.
Moving Past Passive Awareness
Calendar initiatives like National Ovarian Cancer Awareness Month in September generate significant visibility across social platforms. Yet Campbell argues that simply knowing a condition exists does not provide patients or doctors with actionable next steps. To address that shortfall, Not These Ovaries partnered with global advocacy groups to publish a practical patient advocacy resource guide. The guide functions as a centralized manual designed to assist families through diagnosis, treatment protocols, fertility preservation, and long-term care management.
Bridging the gap between general knowledge and practical steps remains the primary objective of this initiative. “Awareness gets you so far, but what are we doing about it?” Campbell explains. “I’m aware that ovarian cancer exists. What do I do about it? This guide helps to answer that question. Rather than keeping these resources strictly within patient communities, the organization distributes the guide directly to primary care physicians. Providing clinicians with clear information on rare ovarian diseases helps ensure that ambiguous symptoms get evaluated thoroughly rather than dismissed. At the same time, giving patients concrete information helps them advocate for themselves during medical consultations. The ultimate objective is fostering clearer communication between patients and their care teams from the very first visit.
Strict Governance in Digital Health
While digital health tools continue to expand across the sector, Campbell has taken a measured approach to technology adoption. The organization built an interactive chat called Hope to help website visitors find answers to complex clinical questions quickly. Instead of relying on open web queries that can surface misleading health advice, the tool operates strictly within a walled garden of verified data. Every article and summary within the database undergoes formal review and approval by a physician before being published.
This tightly controlled framework ensures that users receive reliable clinical guidance in plain language. “We have extremely clear parameters for what Hope can use as information. It takes peer-reviewed papers and our doctor-approved content and digests that information to share it in a layperson’s language, giving users a direct answer without having to search through dozens of articles.” Translating dense medical literature into accessible summaries gives patients the context they need before walking into an examination room. This setup prevents the anxiety that often comes from unmoderated internet searches, while protecting the clinical accuracy of the material. For Campbell, deploying digital tools responsibly means maintaining rigorous medical oversight at every stage. Technology serves to simplify complex information, but clinical accuracy remains non-negotiable.
The Path Toward Individualized Treatment
Early detection in ovarian cancer faces distinct biological hurdles that physical screening cannot easily overcome. Unlike other cancers where physical self-exams or routine screenings are standard, the deep anatomical position of the ovaries makes manual detection impossible. Current blood tests like CA-125 also present frequent false positives and false negatives, making them unreliable for initial diagnostic screening. It is because of these anatomical and diagnostic limits that Campbell looks toward data-driven research to unlock better insights into tumor behavior.
Future clinical advancements will likely depend on uncovering why different tumor types respond differently to standard therapies. “Right now, we have standard treatment protocols that have been recommended for decades that haven’t changed,” Campbell says. “The more we understand about ovarian cancer, the more we know that the treatment is going to change because we can get more precise. Leveraging research to understand the differences in tumor types and individual mutations will be an extreme help because one size does not fit all.”
Follow Not These Ovaries for more insights on ovarian cancer advocacy, patient support resources, and bridging the diagnostic gap through clinical education.
